Transimmune
Private Company
Funding information not available
Overview
Transimmune is a private, pre-clinical stage biotech leveraging a novel dendritic cell platform derived from the mechanistic understanding of Extracorporeal Photopheresis (ECP). Its core technology uses platelet-activated monocytes to generate dendritic cells in hours, promising enhanced potency and point-of-care manufacturing. The company is advancing programs in cancer and infectious disease vaccines, backed by grants and collaborations with academic institutions and industry partners like Mallinckrodt.
Technology Platform
Physiologic dendritic cell manufacturing platform using platelet-activated monocytes to generate dendritic cells ex vivo in hours, enabling potent immune reprogramming for vaccines and tolerogenic therapies.
Opportunities
Risk Factors
Competitive Landscape
Competes with other dendritic cell therapy developers (e.g., DCPrime, Immunicum), mRNA vaccine companies (e.g., Moderna, BioNTech), and broader cell therapy and immunotherapy firms. Differentiation hinges on its physiologic manufacturing process and potential for point-of-care administration.